Nicki Vasquez - Sutro Biopharma Chief Officer
| STRO Stock | USD 2.69 0.09 3.46% |
Insider
Nicki Vasquez is Chief Officer of Sutro Biopharma
| Age | 61 |
| Address | 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 881 6500 |
| Web | https://www.sutrobio.com |
Nicki Vasquez Latest Insider Activity
Tracking and analyzing the buying and selling activities of Nicki Vasquez against Sutro Biopharma stock is an integral part of due diligence when investing in Sutro Biopharma. Nicki Vasquez insider activity provides valuable insight into whether Sutro Biopharma is net buyers or sellers over its current business cycle. Note, Sutro Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sutro Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Nicki Vasquez over six months ago Sale by Nicki Vasquez of 12185 shares of Sutro Biopharma | ||
Nicki Vasquez over a year ago Exercise or conversion by Nicki Vasquez of 3250 shares of Sutro Biopharma subject to Rule 16b-3 | ||
Nicki Vasquez over a year ago Sutro Biopharma exotic insider transaction detected | ||
Nicki Vasquez over a year ago Exercise or conversion by Nicki Vasquez of 6750 shares of Sutro Biopharma subject to Rule 16b-3 |
Sutro Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.184) % which means that it has lost $0.184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1089) %, meaning that it created substantial loss on money invested by shareholders. Sutro Biopharma's management efficiency ratios could be used to measure how well Sutro Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.25. At this time, Sutro Biopharma's Non Current Assets Total are very stable compared to the past year. As of the 29th of November 2024, Asset Turnover is likely to grow to 0.46, while Total Assets are likely to drop about 289.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Pitzner | Molecular Partners AG | N/A | |
| BS CPA | Inhibrx | 42 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Dr III | Cue Biopharma | 48 | |
| James JD | Eliem Therapeutics | 58 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| JD MSc | Cue Biopharma | 61 | |
| Kenneth MD | Cue Biopharma | 64 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Steven Almo | Cue Biopharma | 63 | |
Management Performance
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.18 |
Sutro Biopharma Leadership Team
Elected by the shareholders, the Sutro Biopharma's board of directors comprises two types of representatives: Sutro Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sutro. The board's role is to monitor Sutro Biopharma's management team and ensure that shareholders' interests are well served. Sutro Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sutro Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Leyman, Chief Officer | ||
| Shabbir Anik, Chief Technical Operations Officer | ||
| Edward Albini, CFO Sec | ||
| William JD, CEO Director | ||
| Nicki Vasquez, Chief Officer | ||
| Edward MBA, CFO Secretary | ||
| Annie MBA, VP Relations | ||
| Venkatesh Srinivasan, Chief Officer | ||
| Anne MD, Chief Officer | ||
| Regina Cheng, Vice Controller | ||
| HansPeter Gerber, Chief Officer | ||
| Trevor Hallam, Chief Scientific Officer | ||
| ScD Swartz, Founder | ||
| MA JD, General Counsel | ||
| Jane RPh, Chief Officer | ||
| Linda Fitzpatrick, Chief Officer |
Sutro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sutro Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (7.97) % | ||||
| Current Valuation | (141.58 M) | ||||
| Shares Outstanding | 82.46 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 77.10 % | ||||
| Number Of Shares Shorted | 1.79 M | ||||
| Price To Earning | 53.08 X |
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Sutro Stock
| 0.63 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.52 | ESPR | Esperion Therapeutics | PairCorr |
| 0.51 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.46 | BHC | Bausch Health Companies | PairCorr |
| 0.43 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.